Abstract
Lung cancer is the leading cause of cancer-related death in both men and women. Several types of nanocarriers have succeeded in delivering both chemotherapeutic agents and genes to lung tumor sites. Among them, solid lipid nanoparticles (SLNs) are newly emerging surrogates to traditional colloidal delivery systems which hold great promise in achieving drug localization at the site of action via both passive and active targeting based on their unique features to incorporate hydrophilic or hydrophobic payloads in addition to proteins and nucleic acids. SLNs open novel frontiers for prolonged and site-specific drug and gene delivery. This chapter emphasizes the role of SLNs in drug and gene delivery via different routes of administration (intravenous, oral, or inhalation). In addition, it highlights the safety profile of biocompatible SLNs that are highly tolerable by the lungs for lung cancer management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
